**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 71108

**Manuscript Type:** LETTER TO THE EDITOR

**New treatment for gastroesophageal reflux disease: Traditional medicine, Xiaochaihu decoction**

Xu LY *et al*. New treatment Xiaochaihu decoction

Li-Ying Xu, Bin-Yan Yu, Lu-Sha Cen

**Li-Ying Xu,** Department of Emergency, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China

**Bin-Yan Yu,** Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China

**Lu-Sha Cen,** Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China

**Author contributions:** Xu LY and Cen LS designed the research; Yu BY analyzed the data; Xu LY and Cen LS performed the research, wrote the letter; Cen LS revised the letter.

**Supported by** Scientific Research Project of Zhejiang TCM Science and Technology Programme, No. 2020ZB067, No. 2020ZT001, and No. 2021ZQ031; and National Natural Science Foundation of China, No. 81503522 and No. 82104862.

**Corresponding author: Lu-Sha Cen, PhD, Attending Doctor,** Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. cenlusa2@sina.com

**Received:** August 26, 2021

**Revised:** September 17, 2021

**Accepted: February 23, 2022**

**Published online:**

**Abstract**

Gastroesophageal reflux disease (GERD) has a high prevalence worldwide and limited therapeutic options. Modified Xiaochaihu decoction (MXD), a new therapy for GERD, is a well-designed study that minimizes bias of herb dose. Their research showed MXD had similar therapeutic effect to omeprazole in mild-to-moderate GERD. One limitation of this study was that it lacked records of side effects and rescue medication. As a chronic disease with recurrent symptoms, GERD rehabilitation requires prolonged observation of the clinical course with MXD therapy.

**Key Words:** Gastroesophageal reflux disease; Xiaochaihu decoction; New treatment; Traditional medicine; ModifiedXiaochaihu decoction; Chronic disease

Xu LY, Yu BY, Cen LS. New treatment for gastroesophageal reflux disease: Traditional medicine, Xiaochaihu decoction. *World J Gastroenterol* 2022; In press

**Core Tip:** ModifiedXiaochaihu decoction (MXD) has been applied for gastroesophageal reflux disease (GRED) for thousands of years in Asian countries. A well-designed clinical study and proved that MXD was an ideal optional therapy for GERD. The drug selection of herbal granule makes double-blind research achievable. Side effects and rescue medication should be noted. As a chronic disease, GERD rehabilitation requires prolonged observation of the clinical course with MXD therapy.

**TO THE EDITOR**

We read with interest a clinical study by Li *et al*[1]. The researchers performed a prospective, double-blinded, and double-simulation study on the efficacy of Modified Xiaochaihu decoction (MXD) for gastroesophageal reflux disease (GERD) and its effect on esophageal motility. The study enrolled 288 participants with GERD, and then divided them into the treatment and control groups, receiving MXD plus omeprazole simulation and omeprazole plus MXD simulation, respectively, for 4 wk. The GERD-Q scale score and esophageal manometry were evaluated. The result showed that MXD had a similar ability to increase the pressure at the lower esophageal sphincter and reduce ineffective swallowing, compared with omeprazole in mild-to-moderate GERD. The recurrence rate was significantly lower than that of the control group within 3 mo, on follow-up visits. We greatly appreciate the dedication of the authors towards studying the effect of MXD on GERD as an optional therapy.

As we all know, GERD has a high global prevalence with limited therapeutic options, and its incidence is increasing annually. Patients with GERD present with variety of symptoms including heartburn, effortless regurgitation, dyspepsia, bloating, and abdominal pain or discomfort as well as cough and laryngitis, which severely impact their quality of life[2]. Since the 1990s, proton pump inhibitor (PPI) therapy has evolved as the standard treatment of choice for GERD[3]. However, it has become evident that symptoms attributed to GERD remain despite ongoing PPI treatment in up to 40% of patients[4], and PPI increases the risks of infections, osteoporosis, hepatic failure, pancreatitis, jaundice, and persistent gynecomastia[5-7]. Therefore, multivariable treatment beyond PPI is urgently required.

Traditional Chinese Medicine believes that the herb Chaihu could regulate qi-flow to harmonize digestive disorders. The formula Xiaochaihu decoction, which has demonstrated therapeutic effects such as for nausea, poor appetite, and epigastric distension, has been used in treating GERD for thousands of years in Asian countries. However, high-level evidence-based Traditional Chinese medical research is still lacking and is restricted by many factors. For instance, the herb formula is customized according to patient characteristics including severity of disease, gender, and age. Besides, pharmaceutical effects may be influenced by the way Chinese herbs are decocted. Thus, it is hard to provide the same drug dose for each patient. In this research, drug selection of herbal granule makes double-blind research achievable. For the concealed allocation, herbal granules were supplied instead of traditional decoction, which greatly reduced the bias from herb treatment.

A limitation of this study was a lack of record keeping of the side effects and rescue medications. With the growing popularity of traditional Chinese medicines, reports of herbal side effects are common. Bupleurum, the main component of MXD, was found to increase the risk of chronic hepatotoxicity[8,9]. Meanwhile, Itoh *et al*[10] reported that long-term oral administration of MXD caused cholestatic liver injury, interstitial pneumonia, and even death[10]. Therefore, medical safety evaluation tests, such as liver and kidney function indices, should be assessed. Rescue medication or treatment for these adverse events should also be considered.

Besides, although the sample size was well calculated according to previous literature reports and formula, the sample size for esophageal manometric indicators, which was from 7–52, was relatively small.

The authors mainly focused on the efficiency of MXD therapy for a short duration. As we know, GERD is generally a chronic disease with recurrent symptoms and requires long-term management[11]. Further studies are needed to evaluate the effects of prolonged MXD therapy on GERD rehabilitation.

**REFERENCES**

1 **Li Z**, Tao L, Zhang SS, Sun XH, Chen SN, Wu J. Modified Xiaochaihu Decoction for gastroesophageal reflux disease: A randomized double-simulation controlled trial. *World J Gastroenterol* 2021; **27**: 4710-4721 [PMID: 34366631 DOI: 10.3748/wjg.v27.i28.4710]

2 **Oh TH**. Accuracy of the Diagnosis of GORD by Questionnaire, Physicians and a Trial of Proton Pump Inhibitor Treatment: The Diamond Study (Gut 2010;59:714-721). *J Neurogastroenterol Motil* 2011; **17**: 98-99 [PMID: 21369501 DOI: 10.5056/jnm.2011.17.1.98]

3 **Koop H**. Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading? *Visc Med* 2018; **34**: 110-115 [PMID: 29888239 DOI: 10.1159/000486692]

4 **El-Serag H**, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. *Aliment Pharmacol Ther* 2010; **32**: 720-737 [PMID: 20662774 DOI: 10.1111/j.1365-2036.2010.04406.x]

5 **Madanick RD**. Proton pump inhibitor side effects and drug interactions: much ado about nothing? *Cleve Clin J Med* 2011; **78**: 39-49 [PMID: 21199906 DOI: 10.3949/ccjm.77a.10087]

6 **de Wit NJ**, Numans ME. [New side effects of proton pump inhibitors; time for reflection?]. *Ned Tijdschr Geneeskd* 2016; **160**: D338 [PMID: 27334088]

7 **Igaz I**, Simonyi G, Balogh S, Szathmári M. [Adverse effects of long-term proton-pump inhibitor therapy on adults]. *Orv Hetil* 2018; **159**: 735-740 [PMID: 29730946 DOI: 10.1556/650.2018.31057]

8 **Li X**, Li X, Huang N, Liu R, Sun R. A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins. *Phytomedicine* 2018; **50**: 73-87 [PMID: 30466994 DOI: 10.1016/j.phymed.2018.09.174]

9 **Lee CH**, Wang JD, Chen PC. Risk of liver injury associated with Chinese herbal products containing radix bupleuri in 639,779 patients with hepatitis B virus infection. *PLoS One* 2011; **6**: e16064 [PMID: 21264326 DOI: 10.1371/journal.pone.0016064]

10 **Itoh S**, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang). *Dig Dis Sci* 1995; **40**: 1845-1848 [PMID: 7648990 DOI: 10.1007/BF02212712]

11 **Freston JW**, Triadafilopoulos G. Review article: approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? *Aliment Pharmacol Ther* 2004; **19 Suppl 1**: 35-42 [PMID: 14725577 DOI: 10.1111/j.0953-0673.2004.01837.x]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 26, 2021

**First decision:** September 4, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Tadros M, Tang F **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR